Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNFWOTCMKTS:FFNTFNASDAQ:LBPSWOTCMKTS:OTRAU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNFW180 Life Sciences$0.01-3.4%$0.01$0.00▼$0.04N/AN/A99,252 shs14,188 shsFFNTF4Front Ventures$0.00-66.7%$0.00$0.00▼$0.11N/AN/A1.38 million shs2.13 million shsLBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/AOTRAUOTR Acquisition$9.55-17.2%$9.55$9.20▼$14.23N/AN/A4,515 shs200 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNFW180 Life Sciences-3.45%+1.20%+12.00%-3.45%-19.23%FFNTF4Front Ventures-66.67%-80.00%-85.71%-99.37%-99.89%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%OTRAUOTR Acquisition0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AN/AN/AN/AOTRAUOTR AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNFW180 Life Sciences 0.00N/AN/AN/AFFNTF4Front Ventures 0.00N/AN/AN/ALBPSW4D pharma 0.00N/AN/AN/AOTRAUOTR Acquisition 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/AOTRAUOTR AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/A0.00∞N/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/AOTRAUOTR AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNFW180 Life SciencesN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AOTRAUOTR AcquisitionN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNFW180 Life SciencesN/AFFNTF4Front VenturesN/ALBPSW4D pharmaN/AOTRAUOTR AcquisitionN/AInsider OwnershipCompanyInsider OwnershipATNFW180 Life SciencesN/AFFNTF4Front VenturesN/ALBPSW4D pharmaN/AOTRAUOTR AcquisitionN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNFW180 Life Sciences7N/AN/ANot OptionableFFNTF4Front Ventures460N/AN/ANot OptionableLBPSW4D pharmaN/AN/AN/ANot OptionableOTRAUOTR Acquisition1N/AN/ANot OptionableOTRAU, ATNFW, LBPSW, and FFNTF HeadlinesRecent News About These CompaniesDAT and OTR, embroiled in dispute over factoring, reach settlement and end battleJune 18, 2025 | freightwaves.comGeorgia court determines DAT violated factoring non-compete with OTR CapitalJune 14, 2025 | freightwaves.comYokohama Rubber acquires OTR tire plant in RomaniaMay 23, 2025 | rubberworld.comYokohama buys idled Romanian OTR plant assetsMay 23, 2025 | tirebusiness.comFleetPride Acquires OTR Fleet Service in HoustonMarch 19, 2025 | mdm.comBWG Strategy and OTR Global Rebrand as BWG GlobalFebruary 19, 2025 | tmcnet.comGoodyear completes sale of OTR tire business to Yokohama RubberFebruary 5, 2025 | rubberworld.comYokohama Rubber acquires Goodyear’s OTR business for $905mFebruary 4, 2025 | just-auto.comYokohama completes acquisition of Goodyear's OTR unitFebruary 4, 2025 | tirebusiness.comLanOTR expands into truck tire retreads with Rechapage acquisitionJanuary 2, 2025 | tirebusiness.comMore choice for HGV drivers after OTRA’s tech snapped upSeptember 13, 2024 | motortransport.co.ukYokohama to acquire Goodyear’s OTR businessJuly 23, 2024 | tiretechnologyinternational.comGoodyear Sells OTR Tire Business To Yokohama For $905M: DetailsJuly 22, 2024 | msn.comYokohama to Buy Goodyear’s OTR Tire Business for $905 MillionJuly 22, 2024 | ttnews.comYokohama to acquire Goodyear's OTR business for $905MJuly 22, 2024 | tirebusiness.comDivestiture of non-core assets “progressing well”May 8, 2024 | tyrepress.comOTR Engineered Solutions to open Mexico warehouseApril 30, 2024 | tirebusiness.comConti acquisition of Goodyear OTR ‘a complementary fit’ and analysts’ preferred ‘area for capital allocation’April 26, 2024 | tyrepress.comOtaru: Herring and Glassware; Keeping Alive Otaru's TraditionApril 20, 2024 | www3.nhk.or.jpOTR Solutions acquires back-office automation platform Epay ManagerFebruary 6, 2024 | freightwaves.comMedia Sentiment Over TimeOTRAU, ATNFW, LBPSW, and FFNTF Company Descriptions180 Life Sciences NASDAQ:ATNFW$0.0084 0.00 (-3.45%) As of 06/23/2025 12:48 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.4Front Ventures OTCMKTS:FFNTF$0.0001 0.00 (-66.67%) As of 06/23/2025 03:31 PM Eastern4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.4D pharma NASDAQ:LBPSW4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.OTR Acquisition OTCMKTS:OTRAU$9.55 -1.99 (-17.24%) As of 05/19/2022As of May 19, 2022, OTR Acquisition Corp. was acquired by Comera Life Sciences Holdings, Inc., in a reverse merger transaction. OTR Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
